This is a massive insider buy from a major shareholder that should be read as a strong bullish signal. Traders should monitor for upcoming catalysts such as clinical trial updates or partnership announcements.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 17 $9.94entry
- T+1 · 5mo ago −1.21%α −1.99% · $9.82
- T+5 · 5mo ago −6.24%α −5.20% · $9.32
- T+20 · 4mo ago −9.05%α −10.37% · $9.04
- T+60 · 2mo ago +2.01%α −0.68% · $10.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
RA Capital Management, a director and 10% owner, purchased 1.43 million shares of Artiva Biotherapeutics for $11.14 million across five open-market trades from June 9-12, 2026. The purchase represents approximately 4.9% of the company's $227 million market cap, a highly material insider buying signal that indicates strong conviction in the company's prospects.
Key Financial Metrics
Key Facts
- Total insider purchase of $11.14 million over 5 trades from June 9-12, 2026
- Purchase represents ~4.9% of $227M market cap, well above the 2% materiality threshold
- Only insider is RA Capital Management, L.P., acting as both director and 10% owner
- Prices ranged from $6.91 to $8.99 per share, with largest trades at higher prices
- Recent 30-day insider activity shows $12.3M in total buys vs $450K in sells, indicating net accumulation
Financial Impact
$11.14 million purchase, approximately 4.9% of market cap
Risk Factors
- Biotech single-product risk and clinical-stage volatility
- Insider could be buying to maintain ownership percentage ahead of dilution or strategic move
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001231919-26-000656 |
Track record
33 reports on ARTV
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers